Medigen Biotechnology - Asset Resilience Ratio
Medigen Biotechnology (3176) has an Asset Resilience Ratio of 23.62% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Medigen Biotechnology (3176) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2024)
This chart shows how Medigen Biotechnology's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Medigen Biotechnology.
Liquid Assets Composition Over Time
This chart breaks down Medigen Biotechnology's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of Medigen Biotechnology to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$1.50 Billion | 23.62% |
| Total Liquid Assets | NT$1.50 Billion | 23.62% |
Asset Resilience Insights
- Good Liquidity Position: Medigen Biotechnology maintains a healthy 23.62% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Medigen Biotechnology Industry Peers by Asset Resilience Ratio
Compare Medigen Biotechnology's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for Medigen Biotechnology (2003–2024)
The table below shows the annual Asset Resilience Ratio data for Medigen Biotechnology.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 18.11% | NT$1.22 Billion ≈ $38.29 Million |
NT$6.71 Billion ≈ $211.42 Million |
-9.62pp |
| 2023-12-31 | 27.73% | NT$2.36 Billion ≈ $74.50 Million |
NT$8.53 Billion ≈ $268.65 Million |
-2.67pp |
| 2022-12-31 | 30.40% | NT$3.03 Billion ≈ $95.59 Million |
NT$9.98 Billion ≈ $314.50 Million |
+19.99pp |
| 2021-12-31 | 10.41% | NT$853.60 Million ≈ $26.89 Million |
NT$8.20 Billion ≈ $258.33 Million |
+9.53pp |
| 2020-12-31 | 0.88% | NT$54.20 Million ≈ $1.71 Million |
NT$6.15 Billion ≈ $193.84 Million |
-1.24pp |
| 2019-12-31 | 2.12% | NT$102.42 Million ≈ $3.23 Million |
NT$4.83 Billion ≈ $152.13 Million |
-10.42pp |
| 2018-12-31 | 12.55% | NT$576.89 Million ≈ $18.18 Million |
NT$4.60 Billion ≈ $144.87 Million |
+11.42pp |
| 2017-12-31 | 1.12% | NT$54.71 Million ≈ $1.72 Million |
NT$4.87 Billion ≈ $153.46 Million |
-0.90pp |
| 2016-12-31 | 2.03% | NT$97.75 Million ≈ $3.08 Million |
NT$4.82 Billion ≈ $151.93 Million |
+1.20pp |
| 2015-12-31 | 0.83% | NT$37.34 Million ≈ $1.18 Million |
NT$4.49 Billion ≈ $141.60 Million |
-18.60pp |
| 2014-12-31 | 19.43% | NT$867.15 Million ≈ $27.32 Million |
NT$4.46 Billion ≈ $140.62 Million |
-10.17pp |
| 2013-12-31 | 29.60% | NT$975.04 Million ≈ $30.72 Million |
NT$3.29 Billion ≈ $103.79 Million |
-2.36pp |
| 2012-12-31 | 31.96% | NT$716.00 Million ≈ $22.56 Million |
NT$2.24 Billion ≈ $70.59 Million |
+31.46pp |
| 2011-12-31 | 0.49% | NT$6.00 Million ≈ $189.03K |
NT$1.21 Billion ≈ $38.27 Million |
-18.45pp |
| 2010-12-31 | 18.94% | NT$164.75 Million ≈ $5.19 Million |
NT$869.78 Million ≈ $27.40 Million |
+0.95pp |
| 2009-12-31 | 17.99% | NT$122.22 Million ≈ $3.85 Million |
NT$679.27 Million ≈ $21.40 Million |
+17.99pp |
| 2008-12-31 | 0.00% | NT$5.00K ≈ $157.53 |
NT$680.98 Million ≈ $21.45 Million |
-10.30pp |
| 2007-12-31 | 10.30% | NT$61.11 Million ≈ $1.93 Million |
NT$593.03 Million ≈ $18.68 Million |
+1.46pp |
| 2006-12-31 | 8.85% | NT$65.73 Million ≈ $2.07 Million |
NT$742.89 Million ≈ $23.41 Million |
+3.57pp |
| 2005-12-31 | 5.28% | NT$37.09 Million ≈ $1.17 Million |
NT$702.17 Million ≈ $22.12 Million |
-14.67pp |
| 2004-12-31 | 19.95% | NT$153.12 Million ≈ $4.82 Million |
NT$767.53 Million ≈ $24.18 Million |
-0.82pp |
| 2003-12-31 | 20.77% | NT$200.85 Million ≈ $6.33 Million |
NT$966.81 Million ≈ $30.46 Million |
-- |
About Medigen Biotechnology
Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cell therapy, advanced nucleic acid testing, generic drugs, medical beauty, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has complete… Read more